Form D · Biotechnology
Plakous Therapeutics, Inc.
Winston Salem, NC · CIK 0001709440
Offering snapshot reported Jan 24, 2020 · SEC filing
- Reported sold
- $175K Offering amount: $4M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Mar 8, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 24, 2020 | Initial | $175,000 | No comparison | 3 | SEC filing |
| Jun 16, 2017 | Initial | $10,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-358913
Convertible promissory notes
Source: Form D, filed Jan 24, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert W. Boyce | Executive |
| Allison London Brown | Director |
| Peter Johnson | Director |
| Seth Tomblyn | Director, Executive |
| Scott A. Washburn | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
755 Highland Oaks Drive Suite 103
Winston Salem, NC, 27103
Winston Salem, NC, 27103